Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 19, Art. 29 (pp. 392-406)    |    2018       

»

Pharmacology and laboratory aspects of therapeutic drug monitoring everolimus

Bezvulyak E.I.1,2, Vavilova Т.V.2, Basharin V.А.1, Kutsenko V.P. 3, Zubkova P.Y.2.

Almazov National Medical Research Centre,
St.Petersburg, Akkuratova street, 2; 8-921-404-72-29.
3ФГБОУ "Санкт-Петербургский государственный педиатрический университет" МЗ РФ, г. Санкт-Петербург, ул. Литовская, д.2;8-953-349-49-37.
St.Petersburg State Pediatric Medical University,
St.Petersburg, Alexandra Matrosova street, 22; 8-953-349-49-37.

Brief summary

Everolimus is approved for the prevention of cardiac transplant rejection in Russia. The drug is used in immunosuppressive therapy and has an anti-oncogenic effect, which is very important for patients with suppressed immunity. Everolimus belong to the drugs of critical dose and has a narrow therapeutic index. Small changes in the concentration of everolimus in the blood can lead to a significant reduction in the therapeutic effect or the development of toxic effects. Maintaining optimal therapeutic concentration of the drug in the blood is the most important condition for long-term stable graft function. In the appointment of everolimus therapeutic drug monitoring should be carried out in order to correct the dose. This article presents the features of the pharmacokinetics of everolimus in patients after heart transplantation, the factors affecting the formation of therapeutic concentration, and laboratory methods for monitoring the concentration of everolimus in the blood.


Key words

everolimus, therapeutic drug monitoring, heart transplantation.

Reference list

1. Serdechno - sosydistie zabolevaniya. Osnovnie fakti. // www.who.int - 17.05.2017


2. Obsherossiiskaya obshestvennaya organizaciya transplantologov "Rossiiskoe transplantologicheskoe obshestvo?. Nacionalnie klinicheskie rekomendacii "Transplantaciya serdca". // www.transpl.ru - 2016.


3. Klinicheskie rekomendacii: lekarstvennii monitoring i vzaimozamenyaemost originalnih i genericheskih immynodepressantov s yzkim terapveticheskim indeksom. // www.transpl.ru - 2014.


4. Bradley J.A., Watson C.J.E. MTOR inhibitors: Sirolimus and Everolimus. // Kidney transplantation. - 2013. - Chapter 19 - C.267-286;


5. Holdaas H., Simone De P., Zuckermann A. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update // Journal of Transplantation. - 2016. 2016:4369574, 11 pages.


6. Budde K., Fritsche L., Waiser J. Pharmacokinetics of the immunospressant everolimus in maintenance renal transplant patients. // Eur J Med Res. - 2005. - 10. P.169-74.


7. Halilylin T.R., Garmash I.V., Malaya I.P. Kliniko-farmakologicheskie issledovaniya y pacientov s naryshennoi fynkciei pecheni. // Klinicheskaya farmakologiya i terapiya. - 2012. - T.21 - N2. - S.30-33;


8. Bezvylyak E.I., Melnichenikova O.S., Vavilova T.V. i dr. Optimizaciya monitoringa koncentracii everolimysa y pacientov posle transplantacii serdca na fone patologii pecheni // Eksperimentalnaya i klinicheskaya gastroenterologiya. - 2018. - 150 (2). - S. 68-73.


9. Dumortier J., Dharancy S., Calmus Y.. Use of everolimus in liver transplantation: The French experience. // Transplantation Reviews. - 2016. - T.30 - P. 161 - 170.


10. Shipikova M., Hesselink D.A., Hold D.W., et.al. Therapeutic drug monitoring of everolimus: a consensus report // Ther Drug Monit. - 2016. - 38. - P. 69-143.


11. Esaylenko A.N. Terapevticheskii lekarstvennii monitoring. // Kliniko - laboratornii konsiliym. - 2008. - T.3, N 22 - S. 6-10.


12. Klinicheskaya laboratornaya diagnostika // Nacionalnoe rykovodstvo. - 2013. - T.1 - S.883-918.